Ac-PGP Peptide Inhibits Myofibroblast Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively targeting pathological fibrosis, leading to poor outcomes in chronic lung diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, as they fail to address the persistent activation of tissue myofibroblasts and the imbalance in proline-glycine-proline (PGP) and its acetylated forms.
Innovation Solution
Administering a therapeutically effective amount of a PGP-containing peptide, specifically Ac-PGP, to subjects at risk or with fibrosis, to inhibit myofibroblast activity and restore balance in the PGP and angiotensin-converting enzyme (ACE) pathway, thereby preventing excessive fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat fibrosis, then treatment is provided, but they fail to effectively inhibit myofibroblast activation and collagen deposition, leading to poor outcomes
Solution Approach 1:
The patent uses PGP-containing peptides as intermediary substances that mediate between the existing fibrotic pathway components (collagen, ACE, myofibroblasts) and the desired therapeutic outcome. The PGP peptide acts as a signaling molecule that specifically targets and modulates myofibroblast activity, representing a novel intermediary approach rather than directly inhibiting enzymes or blocking receptors with small molecules
Solution Approach 2:
The patent changes the biochemical parameters of the fibrotic pathway by introducing exogenous PGP peptides that alter the balance between collagen degradation and myofibroblast activation. By modifying the peptide composition (using PGP specifically with particular amino acid sequences) and delivery parameters (dosage, frequency, route of administration), the therapy shifts the system from a pro-fibrotic state to an anti-fibrotic state
2Object-affected harmful factors
If PGP-containing peptides are administered to inhibit myofibroblast activity, then fibrosis is reduced, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent extracts and isolates the specific bioactive PGP peptide sequence from the complex natural collagen degradation pathway. By identifying and using only the critical PGP tripeptide motif (proline-glycine-proline) as the therapeutic agent, the complex natural process is simplified into a discrete, manufacturable peptide product that can be administered without requiring the entire collagen degradation system
Solution Approach 2:
The patent creates synthetic copies of the natural PGP peptide sequence that occurs endogenously during collagen remodeling. These synthesized PGP peptides replicate the exact amino acid sequence and structural properties of the natural molecule, allowing them to bind to and modulate the same cellular receptors and enzymes (such as ACE and myofibroblast surface receptors) without requiring the complex natural production pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of Ac-PGP significantly reduces or prevents fibrosis by inhibiting myofibroblast differentiation and collagen deposition, as demonstrated by reduced lung fibrosis in bleomycin-exposed mice and human IPF patients, indicating a potential novel therapy for pulmonary fibrosis.
Implementation Method 1
Administering a therapeutically effective amount of a PGP-containing peptide, specifically Ac-PGP, to subjects at risk or with fibrosis, to inhibit myofibroblast activity and restore balance in the PGP and angiotensin-converting enzyme (ACE) pathway
Data Source
AI summary
Provided herein are compositions and methods for treating or preventing fibrosis.